



For Immediate Release

Atturos founder and CSO Prof. Stephen Pennington to present at American College of Rheumatology Meeting

Dublin, Ireland, September 5th 2024. Atturos is delighted to announce that Prof. Stephen Pennington our founder and CSO has been selected to make an oral presentation at the American College of Rheumatology meeting in Washington DC, November 14th to 19th 2024. The presentation will report the results of a >1000 patient clinical validation study was undertaken in collaboration with key opinion leading rheumatologists. The presentation is titled **Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA).**

Robert Perryman, CEO commented “We look forward to catching up with our clinician and patient advocate collaborators and introducing RAPsA Dx to a new audience.”

Atturos is preparing to **launch RAPs Dx on the US market** following successful clinical validation studies. RAPsA Dx is a blood-based protein biomarker signature generated by mass spectrometry and analysed by machine learning algorithms. It can distinguish **patients with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA).** There is a large unmet need for such a test.

RAPsA Dx will allow rheumatologists to make the correct diagnosis more rapidly meaning that patients receive the correct diagnosis and treatment as soon as possible. There are over **8m patients in the US with inflammatory arthritis** and in at least **one third it is very difficult to diagnose** their specific condition, this includes **1.5M patients with RA and 800k with PsA.**

For further information please contact:

Robert Perryman, Atturos CEO at robert.perryman@atturos.com

Visit our website at www.Atturos.com